Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
For hypothyroidism patients, less may be more. A new survey of over 900 adults found that levothyroxine monotherapy consistently delivered better quality of life than combination levothyroxine/liothyronine therapy or desiccated thyroid extract. Notably, there wasn't a single quality-of-life measure where the combination treatments came out ahead.
For the many patients who feel dismissed when their thyroid labs look "normal" but they still feel unwell, a new study offers some clarity. A survey of 907 adults with primary hypothyroidism found that those on levothyroxine monotherapy reported better quality of life across nearly every measure compared to those on combination levothyroxine/liothyronine or desiccated thyroid extract (DTE).
Presented at the 2026 American Thyroid Association annual meeting, the study used the ThyPRO-39 questionnaire to assess quality of life. Combination therapy patients fared worse on goiter symptoms, hyperthyroidism, eye symptoms, tiredness, cognition, anxiety, depression, and overall quality of life. DTE users also scored worse on anxiety and overall quality of life compared to the monotherapy group.
Key Takeaways:
Why it matters: These findings push back against growing interest in combination thyroid therapies, suggesting that the standard treatment may still be the best option — though researchers note that more studies are needed to understand individual clinical factors that could influence quality of life outcomes.
